CEDARS SINAI MEDICAL CENTER 4
4 · Prometheus Biosciences, Inc. · Filed Mar 16, 2021
Insider Transaction Report
Form 4
CEDARS SINAI MEDICAL CENTER
10% Owner
Transactions
- Conversion
Common Stock
2021-03-16+361,566→ 5,008,508 total - Conversion
Series C Preferred Stock
2021-03-16−25,000,000→ 0 total→ Common Stock (2,500,000 underlying) - Conversion
Series D-2 Preferred Stock
2021-03-16−3,615,656→ 0 total→ Common Stock (361,566 underlying) - Conversion
Common Stock
2021-03-16+1,200,000→ 1,892,500 total - Conversion
Common Stock
2021-03-16+254,442→ 4,646,942 total - Conversion
Series A Preferred Stock
2021-03-16−1,000,000→ 0 total→ Common Stock (100,000 underlying) - Conversion
Series B Preferred Stock
2021-03-16−12,000,000→ 0 total→ Common Stock (1,200,000 underlying) - Conversion
Common Stock
2021-03-16+100,000→ 692,500 total - Conversion
Common Stock
2021-03-16+2,500,000→ 4,392,500 total - Conversion
Series D-1 Preferred Stock
2021-03-16−2,544,425→ 0 total→ Common Stock (254,442 underlying)
Footnotes (5)
- [F1]The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
- [F2]The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
- [F3]The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
- [F4]The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
- [F5]The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.